Journal of Hepatology
Volume 53, Issue 2 , Pages 225-227 , August 2010

May vaptans contribute to the treatment of refractory ascites?

References 

  1. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176
  2. Moore K, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrosis. Report of the consensus conference of the international ascites club. Hepatology. 2003;38:258–266
  3. Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology. 1987;93(2):234–241
  4. Ginès P, Arroyo V, Vargas V, Planas R, Casafont F, Panés J, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med. 1991;325:829–835
  5. Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites. A meta-analysis of individual data. Gastroenterology. 2007;133:825–834
  6. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study on TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40:629–635
  7. Romanelli RG, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol. 2006;12:1403–1407
  8. Singh V, Dehereendra PC, Singh B, Nain CK, Chawla D, Sharma N, et al. Midodrine versus albumin in the prevention of paracentesis induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008;103:1399–1405
  9. Decaux G, Soupart A, Vassart G. Non-peptidearginine–vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–1631
  10. Gerbes AL, Gülberg V, Gines P, Decaux G, Gross P, Gandjini H, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–939
  11. Gross P. Treatment of hyponatremia. Inter Med. 2008;47:885–891
  12. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA. 2007;297:1319–1331
  13. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional Class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615–1621
  14. Gines P, Wong F, Watson H, Milutinoviv S, Ruiz del Arbol LR, Olteanu D. HypoCat Study investigators. Effects of Satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: randomazed trial. Hepatology. 2008;48:204–213
  15. Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, et al. Effects of a selective vasopressin V2 receptor antagonist, Satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010;53:283–290
  16. Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L. Sodium excretion in response to and selective vasopressin receptor antagonists. J Am Soc Nephrol. 2008;19:1721–1731

PII: S0168-8278(10)00383-1

doi: 10.1016/j.jhep.2010.04.003

Journal of Hepatology
Volume 53, Issue 2 , Pages 225-227 , August 2010

Article Tools